Nicole Mowad-Nassar elected to Resmed's board; Rich Sulpizio to retire after two decades of service.
Quiver AI Summary
Resmed has announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. Mowad-Nassar currently serves as Senior Vice President at AbbVie and leads its Specialty and U.S. Therapeutics Operations, overseeing a $6 billion portfolio and a team of 6,000. With over 30 years of experience in the pharmaceutical industry, she has specialized in commercial strategy and digital innovation, notably leading the integration of AbbVie’s $63 billion acquisition of Allergan. Resmed's Chairman and CEO, Mick Farrell, praised her extensive experience and commitment to patient access and digital engagement. The company also acknowledged Rich Sulpizio's retirement from the board after two decades of service, expressing gratitude for his contributions. Mowad-Nassar will serve as an independent director and join the Compensation and Leadership Development Committee, standing for reelection at the 2025 Annual Meeting of Stockholders.
Potential Positives
- Nicole Mowad-Nassar's extensive experience in strategic, commercial, and operational roles in the pharmaceutical industry enhances Resmed's board with valuable insights, particularly in digital innovation and patient access.
- Her leadership in overseeing a $6 billion commercial portfolio aligns with Resmed's commitment to innovative healthcare solutions, potentially driving future growth.
- The transition in board leadership from Rich Sulpizio, who contributed for 20 years, to a fresh perspective with Mowad-Nassar may invigorate Resmed’s strategic direction and decision-making processes.
Potential Negatives
- The retirement of long-serving board member Rich Sulpizio may create a gap in leadership experience and continuity within the board, raising concerns about stability during the transition.
- Nicole Mowad-Nassar's extensive responsibilities at AbbVie might lead to potential conflicts of interest, given her position in a major competitor within the healthcare sector.
- The reliance on a new board member with significant ties to a competing pharmaceutical company could lead to skepticism regarding Resmed's strategic direction and priorities.
FAQ
Who is Nicole Mowad-Nassar?
Nicole Mowad-Nassar is the Senior Vice President at AbbVie and has recently been elected to Resmed's board of directors.
What is Mowad-Nassar's role at AbbVie?
She serves as President of Specialty and U.S. Therapeutics Operations, overseeing a $6 billion commercial portfolio.
When was Mowad-Nassar elected to the Resmed board?
Nicole Mowad-Nassar was elected to Resmed's board of directors effective August 15, 2025.
What are the main focuses of Mowad-Nassar's career?
Her career focuses on strategic, commercial, and operational expertise in the pharmaceutical and healthcare industries, emphasizing digital innovation.
Who is retiring from Resmed's board?
Rich Sulpizio, who has served on Resmed's board for two decades, will retire following the 2025 Annual Meeting.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RMD Congressional Stock Trading
Members of Congress have traded $RMD stock 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $RMD stock by members of Congress over the last 6 months:
- REPRESENTATIVE KELLY MORRISON has traded it 5 times. They made 0 purchases and 5 sales worth up to $75,000 on 06/04, 04/28.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RMD Insider Trading Activity
$RMD insiders have traded $RMD stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.
Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:
- MICHAEL J. FARRELL (Chief Executive Officer) has made 0 purchases and 6 sales selling 48,054 shares for an estimated $11,770,759.
- KAUSHIK GHOSHAL (Chief Commercial Officer, SaaS) has made 0 purchases and 5 sales selling 18,858 shares for an estimated $4,477,282.
- BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 6 sales selling 13,527 shares for an estimated $3,424,598.
- PETER C FARRELL has made 0 purchases and 5 sales selling 8,945 shares for an estimated $2,115,478.
- WITTE JAN DE sold 2,000 shares for an estimated $486,940
- MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 5 sales selling 285 shares for an estimated $70,296.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RMD Hedge Fund Activity
We have seen 461 institutional investors add shares of $RMD stock to their portfolio, and 451 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 1,479,378 shares (-35.7%) from their portfolio in Q2 2025, for an estimated $381,679,524
- GAMMA INVESTING LLC removed 729,713 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $188,265,954
- NORGES BANK added 669,170 shares (+129.0%) to their portfolio in Q2 2025, for an estimated $172,645,860
- OVERSEA-CHINESE BANKING CORP LTD removed 547,532 shares (-92.7%) from their portfolio in Q2 2025, for an estimated $141,263,256
- MARSHALL WACE, LLP removed 543,857 shares (-97.7%) from their portfolio in Q2 2025, for an estimated $140,315,106
- CONGRESS ASSET MANAGEMENT CO removed 484,773 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $125,071,434
- CITADEL ADVISORS LLC added 328,864 shares (+853.5%) to their portfolio in Q2 2025, for an estimated $84,846,912
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RMD Analyst Ratings
Wall Street analysts have issued reports on $RMD in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 08/01/2025
- RBC Capital issued a "Outperform" rating on 08/01/2025
- Mizuho issued a "Outperform" rating on 08/01/2025
- JP Morgan issued a "Overweight" rating on 04/24/2025
- Keybanc issued a "Overweight" rating on 04/24/2025
- Citigroup issued a "Buy" rating on 03/05/2025
To track analyst ratings and price targets for $RMD, check out Quiver Quantitative's $RMD forecast page.
$RMD Price Targets
Multiple analysts have issued price targets for $RMD recently. We have seen 8 analysts offer price targets for $RMD in the last 6 months, with a median target of $290.0.
Here are some recent targets:
- Adam Maeder from Piper Sandler set a target price of $270.0 on 08/01/2025
- Jonathan Block from Stifel set a target price of $270.0 on 08/01/2025
- Craig Wong-Pan from RBC Capital set a target price of $300.0 on 08/01/2025
- Anthony Petrone from Mizuho set a target price of $290.0 on 08/01/2025
- Brett Fishbin from Keybanc set a target price of $298.0 on 08/01/2025
- Laura Sutcliffe from UBS set a target price of $325.0 on 08/01/2025
- David Low from JP Morgan set a target price of $290.0 on 04/24/2025
Full Release
- Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations
- Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled for November 19, 2025.
Nicole Mowad-Nassar currently serves as President of Specialty and U.S. Therapeutics Operations at AbbVie. She leads a $6 billion commercial portfolio spanning more than 17 therapeutic areas and oversees a workforce of 6,000. Over her 30-year career, she has held senior executive roles across commercial strategy, marketing, digital innovation, patient services, and large-scale business transformation. Her leadership includes both U.S. and global responsibilities, with direct contributions to long-range strategic planning, digital health innovation, and enterprise integration.
At AbbVie, Mowad-Nassar led the commercial integration of the $63 billion Allergan acquisition, one of the largest in industry history. She ensured continuity across product launches, while minimizing operational disruption.
“Nicole’s track record with multiple strategic, commercial, and operational roles, in the US and globally, at one of the world’s largest pharmaceutical companies will add new dimensions of thought and broad healthcare delivery experience to our board,” said Mick Farrell, Resmed’s Chairman and CEO. “Nicole brings a sharp commercial lens, a deep commitment to patient access, and a strong orientation toward digital patient engagement. I am impressed by Nicole’s personal life journey and her professional insight; she will be a great addition to our Resmed board of directors.”
Mowad-Nassar will serve as an independent director and has been appointed to the Compensation and Leadership Development Committee. She will stand for reelection with the rest of Resmed’s board members at the company’s 2025 Annual Meeting of Stockholders.
Rich Sulpizio, who has served on Resmed’s board of directors since 2005, will retire following the 2025 Annual Meeting. During his tenure, Rich has chaired the Compensation Committee, served on the Audit Committee, and most recently chaired the Nominating and Governance committee. Sulpizio is the former President and Chief Operating Officer of Qualcomm, and served on the board of both Qualcomm and CA Technologies.
“Rich has made extraordinary contributions to Resmed’s board over the past two decades,” said Farrell. “He brought energy, candor, and always with a people-first mindset, to every boardroom conversation. Rich has been, and will continue to be, a mentor to me and many other executives in the tech and healthcare industry; I am proud to have served on our Resmed board together, and I wish Rich and his family all the best.”
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at
Resmed.com
and follow @Resmed.
| F or investors | For media |
| + 1 858.836.5971 | +1 619.510.1281 |
| [email protected] | [email protected] |
